Hypertension Journal

Register      Login

VOLUME 2 , ISSUE 3 ( July-September, 2016 ) > List of Articles

RESEARCH ARTICLE

Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus

Gary E Sander, Camilo Fernandez, Philip J Kadowitz, Thomas D Giles

Citation Information : Sander GE, Fernandez C, Kadowitz PJ, Giles TD. Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. Hypertens J 2016; 2 (3):139-144.

DOI: 10.5005/jp-journals-10043-0046

Published Online: 00-09-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim

To provide a perspective on the effect of Sodium-glucose co-transporter 2 (SGLT2) inhibitors on cardiovascular (CV) risk reduction in type 2 diabetes mellitus (DM) patients.

Background

Sodium-glucose co-transporter 2 inhibitors have been introduced as hypoglycemic agents for the treatment of type 2 diabetes by the unique mechanism of inhibiting the SGLT2 protein-mediated uptake of glucose by the kidney, producing an osmotic diuresis and some degree of natriuresis. The Food and Drug Administration (FDA) has thus far approved three drugs of this class for the treatment of type 2 diabetes – empagliflozin, canagliflozin, and dapagliflozin.

Review results

During the clinical trials performed to establish efficacy in diabetes control, these drugs were found to exert a range of beneficial effects beyond glucose lowering. The most interesting of these has been a reduction in systolic blood pressure (SBP) by an average of 3 to 5 mm Hg and diastolic blood pressure (DBP) of 2 to 3 mm Hg. A larger and even more unexpected discovery was that empagliflozin reduced the primary outcome of death from CV causes and nonfatal myocardial infarctions and strokes from 12.1% in the placebo group to 10.5% in an empagliflozin group in a clinical trial enrolling high CV risk patients. Overall, there was a 30 to 40% reduction in heart failure hospitalizations (HFHs) and all-cause deaths, with the event reduction appearing within the first 6 months and persisting to the trial conclusion.

Conclusion

The mechanisms for the aforementioned impressive beneficial events remain unclear, but may involve improvements in such parameters as blood pressure, vascular volume, myocardial glucose availability, reduced arterial vascular stiffness, and improvements in autonomic nervous system function. At this time, all approved SGLT2 inhibitors appear similar in pharmacological actions. Clinical trials are now in progress – or under development – that will further explore the CV actions and outcomes of these drugs.

Clinical significance

This review may aid to unify the existing knowledge on SGLT2 inhibitors and CV risk reduction, and set the path for further research endeavors to clarify mechanisms of action associated with additional CV benefits.

How to cite this article

Sander GE, Fernandez C, Kadowitz PJ, Giles TD. Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. Hypertens J 2016;2(3):139-144.


PDF Share
  1. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens 2015 Sep;24(5):463-469.
  2. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005 Dec;54(12):3427-3434.
  3. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014 Feb 4;129(5):587-597.
  4. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015 Mar;12(2):90-100.
  5. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. Curr Opin Nephrol Hypertens 2016 Mar;25(2):81-86.
  6. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014 May;8(5):330-339.
  7. Blood pressure reduction: an added benefit of sodium-glucose cotransporter inhibitors in patients with type 2 diabetes. Diabetes Care 2015 Mar;38(3):429-430.
  8. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013 Aug;159(4):262-274.
  9. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014 Apr;8(4):262-275.
  10. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016 Aug;18(8):783-794.
  11. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab 2015 Aug;17(8):805-808.
  12. Empaglifloin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 Nov 26;373(22): 2117-2128.
  13. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016 May;4(5):411-419.
  14. Reduction in cardiovascular an all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis. Diabetes Metab 2016 Apr;42(2):71-76.
  15. Prehypertension: defining the transitional phenotype. Curr Hypertens Rep 2016 Jan;18(1):2.
  16. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005 May;25(5):932-943.
  17. Sodium intake and vascular stiffness in hypertension. Hypertension 2009 Aug;54(2):203-209.
  18. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014 Jan 29;13:28-36.
  19. Treatment of hypertension and metabolic syndrome: lowering blood pressure is not enough for organ protection, new approach-arterial destiffening. Curr Hypertens Rep 2014 Oct;16(10):479.
  20. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014 Feb;124(2):509-514.
  21. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013 Sep;15(9):853-862.
  22. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014 Feb;124(2):499-508.
  23. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence. Diabetes Metab 2014 Dec;40(6 Suppl 1):S4-S11.
  24. Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: involvement of PI3K but not cAMP. Am J Physiol Endocrinol Metab 2008 Jul;295(1):E155-E161.
  25. Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 2015 Dec;3(12):929-930.
  26. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 2016 Jul;59(7):1333-1339.
  27. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovasc Diabetol 2016 Apr 4;15(1):57.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.